Selected Grants
An open-label, Phase 1b study to evaluate the safety and tolerability of eflornithine plus temozolomide in patients with newly diagnosed glioblastoma
Clinical TrialPrincipal Investigator · Awarded by Orbus Therapeutics, Inc. · 2024 - 2028A Phase 1 Trial of D2C7-IT in Combination with an Fc-engineered Anti-CD40 Monoclonal Antibody (2141-V11) Administered Intratumorally via Convection-Enhanced Delivery Followed by Perilymphatic Injections of 2141-V11 and Assessment of the Tumor Monorai
Clinical TrialPrincipal Investigator · Awarded by Exvade Bioscience Inc. · 2024 - 2027Randomized Phase 2 (Ph2) clinical trial of Lerapolturev (previously known as PVSRIPO) in recurrent glioblastoma (rGBM)
Clinical TrialCo-Principal Investigator · Awarded by Brain Tumor Research Charity · 2024 - 2027Phase I open label ascending dose study to assess the feasibility and safety of intermittent infusions of MTX110 administered by convection-enhanced delivery (CED) as a monotherapy or in combination with lomustine in patients with recurrent glioblast
Clinical TrialPrincipal Investigator · Awarded by Midatech Pharma Plc · 2022 - 2026Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
Clinical TrialSignificant Contributor · Awarded by National Institutes of Health · 2014 - 2023Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas
ResearchCo Investigator · Awarded by National Institutes of Health · 2015 - 2022Phase 3 randomized, open-label study to evaluate Eflornithine with Lomustine compared to Lomustine (STELLAR) alone in patients with Anaplastic Astrocytoma
Clinical TrialPrincipal Investigator · Awarded by Orbus Therapeutics, Inc. · 2016 - 2022Establishing a Rationale for PVSRIPO Immunotherapy in Newly Diagnosed GBM
ResearchInvestigator · Awarded by National Brain Tumor Society · 2019 - 2022An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults with Glioblastoma at First Recurrence or Progression
Clinical TrialPrincipal Investigator · Awarded by Medicenna Therapeutics, Inc. · 2017 - 2022Phase 2 study of SYM004 for adult patients with recurrent glioblastoma
Clinical TrialPrincipal Investigator · Awarded by Symphogen A/S · 2015 - 2021Phase 1 Multicenter, Open-Label, Dose-Escalation, Combination Study of Marizomib and Bevacizumab-Naive Subjects with Grade IV Malignant Glioma
Clinical TrialPrincipal Investigator · Awarded by Celgene Research and Development · 2015 - 2021A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06840003 in Patients with Malignant Glioma
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2016 - 2020Phase 1b, Multicenter, Open-Label Study of Marizomib with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma. MRZ112
Clinical TrialPrincipal Investigator · Awarded by Triphase Research and Development Corp · 2016 - 2020Development of a Therapeutic for Brain Tumor Immunotherapy
ResearchInvestigator · Awarded by National Institutes of Health · 2018 - 2019Combining PVSRIPO Immunotherapy with Lomustine for the Treatment of Recurrent GBM
ResearchCo-Principal Investigator · Awarded by National Brain Tumor Society · 2017 - 2019A Phase 1 Study of PTC in Patients with Advanced Solid Tumors
ResearchPrincipal Investigator · Awarded by PTC Therapeutics, Inc · 2016 - 2017Phase I/II Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination with Lomustine for Bevacizumab-Niave patients with Recurrent WHO grade IV Malignant Glioma. Study#2
Clinical TrialPrincipal Investigator · Awarded by Tactical Therapeutics, Inc. · 2013 - 2016External Relationships
- Biodexa
- Chimerix, Inc.
- Istari Oncology
- Orbus Therapeutics, Inc.
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.